Can I Take Green Tea Extract (EGCG) with Losartan?

What Is Losartan and How Does It Work?

Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension, reduce the risk of stroke in patients with left ventricular hypertrophy, and slow the progression of diabetic nephropathy in patients with type 2 diabetes. It is one of the most prescribed medications in the United States, with tens of millions of patients taking it daily.

Losartan's Metabolic Pathway: Why CYP2C9 Matters

Losartan itself is a prodrug. After absorption, roughly 14% of an oral dose is converted by cytochrome P450 enzyme CYP2C9 (with minor contributions from CYP3A4) into its active carboxylic acid metabolite, E-3174 [1]. E-3174 is 10 to 40 times more potent at the AT1 receptor than the parent drug [2]. Anything that slows CYP2C9 activity reduces the formation of E-3174, which could, in principle, blunt losartan's blood-pressure-lowering effect.

This is why the CYP2C9 inhibitory potential of EGCG matters clinically. It is not a theoretical concern plucked from a textbook. It is a mechanistic pathway with real downstream consequences for blood pressure control.

Who Prescribes Losartan?

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) recognized ARBs as first-line agents in several patient populations, particularly those with diabetic nephropathy or heart failure with reduced ejection fraction [3]. The 2023 European Society of Hypertension guidelines similarly list ARBs among preferred first-line agents [4]. Patients prescribed losartan often have comorbidities that make blood pressure control medically important, which raises the stakes of any interaction that changes drug efficacy.

What Is Green Tea Extract (EGCG)?

Green tea extract is a concentrated form of the polyphenols found in Camellia sinensis leaves. The dominant bioactive polyphenol is epigallocatechin-3-gallate (EGCG), which may account for 50-80% of total catechin content in standardized extracts. Brewed green tea contains roughly 50-150 mg of EGCG per 8-ounce cup. Supplement capsules marketed for weight loss, antioxidant support, or metabolic health frequently contain 400-1,000 mg of EGCG per serving, and some formulas combine multiple servings daily.

Why People Take EGCG Supplements

EGCG has been studied for weight management, lipid reduction, glucose regulation, and antioxidant effects. A 2020 meta-analysis of 27 randomized trials found that green tea catechins reduced systolic blood pressure by a mean of 1.98 mmHg and diastolic blood pressure by 1.92 mmHg, though effects were modest and heterogeneous across trials [5]. That mild antihypertensive signal is one reason patients prescribed losartan sometimes ask about taking green tea extract alongside it.

Concentration Matters: Dietary vs. Supplemental EGCG

The distinction between drinking green tea and taking a concentrated extract is not semantic. It is a dose difference of roughly 5 to 20 times. A person drinking three cups of green tea daily ingests perhaps 200-400 mg of EGCG in a food matrix alongside water, fiber, and other polyphenols that may modify absorption. Someone swallowing two 500-mg EGCG capsules on an empty stomach delivers a bolus of 1,000 mg of concentrated catechin to the portal circulation, which is a substantially different pharmacokinetic event with a different liver exposure profile.

The CYP2C9 Interaction: What the Evidence Shows

The most pharmacologically significant concern with combining EGCG and losartan is CYP2C9 inhibition.

In-Vitro and Animal Evidence

Several in-vitro studies have demonstrated that EGCG inhibits CYP2C9 activity. A 2010 study published in Drug Metabolism and Pharmacokinetics reported that EGCG inhibited CYP2C9-mediated metabolism in human liver microsomes with an IC50 in the low-micromolar range [6]. CYP2C9 metabolizes a wide range of drugs beyond losartan, including warfarin, phenytoin, and several nonsteroidal anti-inflammatory drugs. The inhibitory potential is considered moderate rather than potent compared to drugs like fluconazole, but it is not negligible.

Animal studies have shown pharmacokinetic changes with co-administration. A 2012 study in rats found that oral green tea polyphenols significantly increased the plasma area under the curve (AUC) of CYP2C9 substrate drugs, suggesting reduced metabolic clearance [7].

Clinical Evidence Gaps

Controlled pharmacokinetic studies specifically measuring E-3174 formation in humans taking EGCG supplements alongside losartan are limited. This is a genuine evidence gap. Most clinical interaction data come from case reports, pharmacovigilance databases, and extrapolation from in-vitro findings. The absence of a definitive human pharmacokinetic trial does not make the interaction implausible. It means the risk magnitude is uncertain, not that the risk is zero.

Practical Consequence of CYP2C9 Inhibition

If EGCG meaningfully inhibits CYP2C9, less losartan is converted to E-3174. Blood pressure control may deteriorate without any obvious symptom until a hypertensive event occurs. Patients monitoring their blood pressure at home may notice readings climbing over days to weeks while attributing the change to stress, salt intake, or seasonal variation rather than a supplement interaction.

Hepatotoxicity Risk: A Separate and Serious Concern

The liver injury question is independent of the CYP2C9 interaction and applies to anyone taking high-dose EGCG, regardless of what other medications they use. The combination with losartan adds a second layer of concern.

EGCG and Drug-Induced Liver Injury

The European Food Safety Authority (EFSA) conducted a thorough safety assessment of green tea catechins in 2018 and concluded that "EGCG doses of 800 mg/day or more are associated with signs of liver damage in some human studies" [8]. The EFSA Panel on Food Additives and Nutrient Sources added to Food (ANS) specifically identified fasting intake (taking supplements on an empty stomach) as a factor that increases peak EGCG plasma concentrations and may increase hepatotoxicity risk.

Case reports of acute hepatitis, cholestatic jaundice, and fulminant liver failure linked to EGCG-containing supplements appear in the medical literature. A 2016 review in Food and Chemical Toxicology identified more than 70 published case reports of hepatotoxicity associated with green tea preparations, predominantly concentrated extracts rather than beverage consumption [9].

Losartan's Own Liver Signal

Losartan itself carries a rare but documented risk of hepatotoxicity. The FDA-approved prescribing information for Cozaar (losartan) notes that post-marketing reports include liver function test abnormalities and hepatitis [10]. The incidence is considered very rare (fewer than 1 in 10,000 patients) but is not zero. Combining an ARB with an established hepatotoxic supplement creates the possibility of additive liver stress, even if the mechanisms differ.

Who Faces the Highest Hepatotoxicity Risk?

Patients with pre-existing liver disease, elevated baseline transaminases, alcohol use disorder, or other hepatotoxic medications (statins, methotrexate, acetaminophen at high doses) face a higher baseline risk. Age above 60 and female sex have been identified as demographic risk factors for drug-induced liver injury generally, based on the Drug-Induced Liver Injury Network (DILIN) registry data [11].

Pharmacodynamic Overlap: Blood Pressure Additive Effects

Beyond the enzyme interaction and hepatotoxicity concerns, there is a third, generally minor issue: both losartan and EGCG lower blood pressure through different mechanisms, and the effects may add together.

Magnitude of Each Effect

Losartan at 50-100 mg/day typically reduces systolic blood pressure by 10-15 mmHg in hypertensive patients. The antihypertensive effect of EGCG supplementation, when observed at all, averages under 2 mmHg systolic in meta-analyses [5]. That additive effect is small and probably not clinically significant for most patients. A person with well-controlled hypertension at 120/78 mmHg is unlikely to experience symptomatic hypotension from adding a moderate-dose EGCG supplement.

The concern applies primarily to patients whose blood pressure is already on the lower end of the therapeutic target, older adults with orthostatic tendency, or those also taking diuretics or calcium channel blockers alongside losartan.

Symptoms of Excess Blood Pressure Lowering

Lightheadedness on standing, fatigue, or presyncope are signs that blood pressure may be running too low. Patients should be counseled to check their blood pressure at home after starting any new supplement and report readings consistently below 100/60 mmHg.

Caffeine in Green Tea Extracts: A Compounding Variable

Many green tea extract products contain residual caffeine. Caffeine transiently raises blood pressure through sympathetic nervous system activation, potentially offsetting EGCG's mild antihypertensive effect or creating variable, unpredictable blood pressure patterns. A product delivering 400 mg of EGCG alongside 100 mg of caffeine creates a mixed pharmacodynamic picture that is harder to predict than either substance alone. Patients should choose caffeine-free or decaffeinated EGCG preparations when possible, particularly if they are sensitive to caffeine or have arrhythmias.

What the Guidelines Say About Supplement-Drug Interactions in Hypertension

The 2023 ACC/AHA Hypertension Guideline Writing Committee states that clinicians should routinely ask patients about dietary supplements, herbal products, and over-the-counter medications, because these substances can alter antihypertensive drug efficacy and safety [12]. The guideline does not specifically address EGCG and ARBs, but it establishes the disclosure expectation clearly: patients on antihypertensive therapy should not add supplements without informing their prescriber.

The American Association of Clinical Endocrinology (AACE) similarly recommends thorough medication reconciliation including supplements for patients with metabolic comorbidities [13].

Practical Guidance: Can You Take EGCG with Losartan?

The answer depends on form and dose.

Dietary Green Tea (Low Risk)

Drinking 2 to 4 cups of brewed green tea per day (delivering roughly 100-400 mg of EGCG in a food matrix) carries a low interaction risk with losartan. No clinically meaningful case reports have implicated standard dietary green tea consumption in either hepatotoxicity or significant CYP2C9 drug interactions. This level of intake is generally considered reasonable for most patients on losartan.

Low-to-Moderate Dose Supplements (Monitor)

Standardized EGCG supplements at 200-400 mg/day, taken with food, fall below the EFSA's 800 mg/day safety threshold. This range may be acceptable for patients with normal baseline liver function, no additional hepatotoxic drugs, and regular blood pressure monitoring. A pharmacist or prescriber review before starting is appropriate.

High-Dose EGCG Supplements (Avoid Without Physician Oversight)

EGCG doses at 800 mg/day or above carry a documented hepatotoxicity risk and are more likely to produce CYP2C9 inhibition of clinical relevance. This range should not be combined with losartan without explicit physician clearance and baseline liver function testing (ALT, AST, bilirubin) followed by repeat testing at 4 to 8 weeks after initiation.

If You Are Already Taking Both

Do not stop either abruptly without guidance. Stopping losartan suddenly can cause blood pressure rebound. Check your blood pressure over the next three to seven days. If readings are higher than your established baseline, contact your prescriber. Request liver function testing if you have been taking high-dose EGCG for more than four weeks. Bring the supplement bottle to your next appointment so the clinician can assess the exact dose and formulation.

Monitoring Checklist for Patients Combining EGCG and Losartan

| Parameter | Baseline | Week 4-8 | Ongoing | |---|---|---|---| | ALT and AST | Yes | Yes if EGCG > 400 mg/day | Every 3-6 months | | Bilirubin | Yes if liver risk factors present | Yes | As clinically indicated | | Systolic blood pressure | Yes | Yes | Per standard hypertension monitoring | | EGCG product and dose | Document | Reassess | Annual medication reconciliation | | Caffeine content of EGCG product | Assess | N/A | If arrhythmia develops |

Key Takeaways for Clinicians Prescribing Losartan

Patients with hypertension are frequently interested in "natural" adjuncts to their medications, and green tea extract is among the most commonly used. A 2019 survey published in JAMA Internal Medicine found that 35% of U.S. Adults taking prescription medications also used dietary supplements, yet fewer than one-third disclosed this to their physician [14]. Proactively asking about EGCG and other supplement use at every antihypertensive medication review is the most effective way to catch this combination before it causes harm.

Documentation and Disclosure

When a patient discloses EGCG use, document the product name, dose, frequency, and whether it is taken with or without food. Note whether caffeine is present in the formulation. This information shapes the risk assessment meaningfully.

When to Refer

Patients with ALT or AST values greater than three times the upper limit of normal after starting EGCG should discontinue the supplement and be evaluated for drug-induced liver injury, regardless of losartan co-administration. The Council for Responsible Nutrition's Hepatotoxicity Working Group recommends this threshold for clinical action [15].